Multicenter validation of spin-density projection-assisted R2-MRI for the noninvasive measurement of liver iron concentration von St Pierre, Tim G., El-Beshlawy, Amal, Elalfy, Mohsen, Al Jefri, Abdullah, Al Zir, Kusai, Daar, Shahina, Habr, Dany, Kriemler-Krahn, Ulrike, Taher, Ali

Volltext

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study von Taher, Ali, El-Beshlawy, Amal, Elalfy, Mohsen S., Al Zir, Kusai, Daar, Shahina, Habr, Dany, Kriemler-Krahn, Ulrike, Hmissi, Abdel, Al Jefri, Abdullah

Volltext

Prevention of Hemoglobinopathies in Syria von Al-Zir, Kusai Nasser

Volltext

Importance of optimal dosing ≥30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia von Taher, Ali, Elalfy, Mohsen S., Al Zir, Kusai, Daar, Shahina, Al Jefri, Abdullah, Habr, Dany, Kriemler-Krahn, Ulrike, El-Ali, Ali, Roubert, Bernard, El-Beshlawy, Amal

Volltext

Improved Treatment Satisfaction and Convenience with Deferasirox in Iron-Overloaded Patients with β-Thalassemia: Results from the ESCALATOR Trial von Taher, Ali, Al Jefri, Abdullah, Elalfy, Mohsen Saleh, Al Zir, Kusai, Daar, Shahina, Rofail, Diana, Baladi, Jean François, Habr, Dany, Kriemler-Krahn, Ulrike, El-Beshlawy, Amal

Volltext

Multicenter Validation of Spin-Density Projection-Assisted R2-MRI for the Non-Invasive Measurement of Liver Iron Concentration von St Pierre, Timothy G, El-Beshlawy, Amal, Elalfy, Mohsen Saleh, Al Jefri, Abdullah, Al Zir, Kusai, Daar, Shahina, Habr, Dany, Kriemler-Krahn, Ulrike, Taher, Ali

Volltext

Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: results from the ESCALATOR study von Taher, Ali, Elalfy, Mohsen S., Al Zir, Kusai, Daar, Shahina, Al Jefri, Abdullah, Habr, Dany, Kriemler-Krahn, Ulrike, Roubert, Bernard, El-Beshlawy, Amal

Volltext

Deferasirox (Exjade®) Treatment in Pediatric β-Thalassemia Patients with High Iron Burden: 2.8 Years Results from ESCALATOR Trial von Taher, Ali, Jefri, Abdullah Al, Elalfy, Mohsen Saleh, Zir, Kusai Al, Daar, Shahina, Damanhouri, Ghazi, Kriemler-Krahn, Ulrike, Habr, Dany, Hmissi, Abdel, El-Beshlawy, Amal

Volltext

Efficacy and Safety of Once-Daily Oral Deferasirox (Exjade®) during a Median of 2.7 Years of Treatment in Heavily Iron-Overloaded Patients with β-Thalassemia von Taher, Ali, El-Beshlawy, Amal, Elalfy, Mohsen Saleh, Zir, Kusai Al, Daar, Shahina, Damanhouri, Ghazi, Habr, Dany, Kriemler-Krahn, Ulrike, Hmissi, Abdel, Jefri, Abdullah Al

Volltext

Oral Deferasirox (Exjade®, ICL670) Is Effective, with a Clinically Manageable Safety Profile, in Pediatric β-Thalassemia Patients with High Iron Burden von Taher, Ali, Jefri, Abdullah Al, Elalfy, Mohsen Saleh, Zir, Kusai Al, Daar, Shahina, Damanhouri, Ghazi, Kriemler-Krahn, Ulrike, Pfluger, Dietrich, Hadler, Dominik, El-Beshlawy, Amal

Volltext

Deferasirox (Exjade®, ICL670) Treatment of Inadequately Chelated β-Thalassemia Patients from the Middle East: The ESCALATOR Trial von Taher, Ali, El-Beshlawy, Amal, Al Jefri, Abdullah, El Alfy, Mohsen, Al Zir, Kusai, Daar, Shahina, Al-Damanhouri, Ghazi, Hadler, Dietrich, Krahn, Ulrike

Volltext